Skip to main content
08 Jul | 2021

Discover BBRC’s participation in the Alzheimer’s Association International Conference (AAIC 2021)

The team of the research center of the Pasqual Maragall Foundation presents 6 oral communications and 15 posters, and participates in about fifteen international collaborations

01 Jul | 2021

The BBRC launches Beta-AARC, a cohort study to identify blood biomarkers from the onset of Alzheimer's

The Beta-AARC cohort study aims to advance the early detection of blood biomarkers that indicate pathophysiological changes related to Alzheimer's in people who experience a subjective deterioration of memory.

30 Jun | 2021

Marc Suárez-Calvet, head of the BBRC Group of Biomarkers in Fluids and Translational Neurology

Under the direction of Dr. Suárez-Calvet, the center will have the creation of a state-of-the-art laboratory focused on the development and validation of new biomarkers and will also analyze blood factors that may have a rejuvenating effect on the brain.

22 Jun | 2021

“A key year for science”: the 2020 Report of the Barcelonaβeta Brain Research Center is now available

The Pasqual Maragall Foundation and its research center, the Barcelonaβeta Brain Research Center (BBRC), have published the 2020 Activity Report; a collection of the most outstanding information on the scientific, social and economic activity of the two entities.

17 Jun | 2021

The BBRC participates in the City and Science Biennial 2021 with a talk on food and brain health

Within the framework of the Science Festival, Dr. Aleix Sala gave the talk 'From the plate to the brain'

16 Jun | 2021

Weight loss may be an indicator of an increased risk of developing Alzheimer's disease

A study led by the BBRC, with the support of the “la Caixa” Foundation, suggests that people at increased risk of developing Alzheimer's experience weight loss that would precede cognitive impairment.

14 Jun | 2021

The United States approves the commercialization of a drug that could slow down Alzheimer's disease

The last drug approved by the FDA was in 2003, and until now any treatment has proved to slow down the progression of the disease.

07 May | 2021

Dra. Eider Arenaza-Urquijo has been elected Vice President of an ISTAART Area of professional interest

The researcher of the Clinical Research Group, Biomarkers and Risk Factors of the BBRC will vice-chair the group "Reserve, Resilience and Protective Factors of the International Society to advance research and treatment of Alzheimer’s

14 Apr | 2021

Dr. José Luis Molinuevo is named an honorary member and scientific consultant of the BBRC

The former director of the BBRC's Alzheimer's Prevention Program will occasionally advise the Center's management on issues related to research in the field of Alzheimer's and other neurodegenerative diseases